BACKGROUND Human papillomavirus (HPV) is one of the most common sexually transmitted infections worldwide and the association between HPV infection and genital cancers has been well established. This study concerned the possible role of HPV infection in colorectal carcinoma (CRC) in the Iranian population. MATERIALS AND METHODS We examined 80 tissues obtained from patients with colorectal can...

In 2013, approximately one-third of US adolescent males age 13-17 y had received ≥1 doses of HPV vaccines and only 14% had received ≥3 doses. This study used a nationally representative, online survey to explore experiences and attitudes related to HPV vaccination among parents with adolescent sons. Analyses compared the perspective of parents who do not intend to initiate HPV vaccine for ≥1 ad...

Cervical cancer is one of the most common cancers in women worldwide and persistent infection with human papilloma virus (HPV)s is considered to be the major risk factor. Millions of women are currently infected with high risk genotypes. Therefore, it is imperative to develop therapeutic vaccines to eliminate established infection or HPV-related disease. In the current study, we generated two p...

Two prophylactic vaccines against HPV16 and 18 infections are commercially available. Published clinical trials with these HPV vaccines report their use in protection against cervical CIN2+ if girls are vaccinated before their sexual debut. Even though HPV 16 and 18 cause approximately 70% of cervical cancer and an almost 100% of effectiveness would be expected against these cancers, other type...

Recently, two prophylactic vaccines against the most significant oncogenic human papillomaviruses (HPV; 16 and 18) became available that efficiently protect against persistent HPV infection and cancer precursors. However, clinical trials performed with these vaccines did not provide evidence that they would influence the natural history of prevalent HPV infections, that is, their eventual malig...

Prophylactic vaccines for genital human papillomavirus (HPV) infection have been shown to be feasible in animal models, and suitable vaccine material based on virus-like particles can be produced in bulk at reasonable cost. Initiation of phase III clinical trials will follow definition of trial outcome measures through further epidemiological studies, and development of assays of host protectiv...

Considered a highly prevalent infection throughout the world, the human papillomavirus (HPV) is a DNA virus that infects the genital mucosa and has high carcinogenic potential, being related to an increased risk of lower genital tract lesions, such as cervical cancer. This cancer is responsible for the deaths of about 231,000 women per year worldwide, which means that HPV is a major problem for...

Background HPV-associated ano-genital infections represent the most common sexually-transmitted disease in the general population. The incidence of HPV-associated cancers has been increasing in HIV-infected patients. HPV vaccination may be an approach to reduce the risk of HPVassociated cancers in HIV-infected patients and a combined strategy of screening and vaccination may guarantee an adequa...

AbstractObjective To improve the knowledge, awareness, and attitude (KAA) among health care providers (HCPs) regarding Human Papilloma Virus vaccination (HPV-V), Lebanese Society of Obstetrics Gynecology (LSOG) has regularly organized educational meetings, symposia, workshops. Methods We conducted two sets surveys attendees LSOG congresses in 2009 2018 to assess their...

BACKGROUND Human papillomavirus (HPV) vaccines are widely available and there have been studies exploring their potential clinical impact and cost-effectiveness. However, few studies have compared the cost-effectiveness among the 2 main vaccines available - a bivalent vaccine against HPV 16/18, and a quadrivalent vaccine against 6/11/16/18. We explore the cost-effectiveness of these two HPV vac...